Dr Michael Weller has been Chairman of the Department of Neurology at the University Hospital Zurich, Switzerland, since 2008. He qualified in medicine in Cologne, Germany, after completing his thesis on proliferative disorders of the retina. A postdoctoral fellowship at the Department of Clinical Immunology, University Hospital Zurich, Switzerland, followed where he identified death receptor targeting as a potential treatment strategy for malignant gliomas. In 2005, he was appointed Chairman of the Department of General Neurology at the University Hospital Tübingen, Germany, where he had previously received his education in clinical neurology.
Dr Weller has received several awards in recognition of his important contributions to cancer research, including the German Cancer Award in 2007. He served as the Chairman of the Neuro-Oncology Group of the German Cancer Society from 2001-2008. He is the Chairman of the German Glioma Network of the German Cancer Council, joined the Executive Board of the European Association for Neuro-Oncology (EANO) in 2010 and was elected President of EANO in 2014.
Dr Weller was involved in major practice-changing clinical trials including the registration trial for temozolomide in glioblastoma and served as PI on the NOA-03, NOA-04, NOA-08 and G-PCNSL-SG-1 trials in Germany and the DIRECTOR and ARTE trials in Switzerland. He is also a member of the editorial boards of the Journal of Neurochemistry, Journal of Neuro-Oncology, Brain and Glia, and he was the Associate Editor Europe of Neuro-Oncology from 2006-2013. Dr Weller has co-authored more than 550 original publications in peer-reviewed journals, including The New England Journal of Medicine, Science, Nature, Nature Medicine, Lancet Oncology, Proceedings of the National Academy of Sciences of the United States of America, The Journal of Clinical Investigation, and The Journal of Clinical Oncology.